English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Analysis of micro RNA  (mi RNA ) expression signatures in prostate cancer ( PC a) and castration‐resistant  PC a has revealed that  mi RNA ‐223  is significantly downregulated in cancer tissues, suggesting that  miR‐223  acts as a tumor‐suppressive mi RNA  by targeting oncogenes. The aim of this study was to investigate the functional roles of  miR‐223  and identify downstream oncogenic targets regulated by  miR‐223  in  PC a cells. Functional studies of  miR‐223  were carried out to investigate cell proliferation, migration, and invasion using  PC 3 and  PC 3M  PC a cell lines. Restoration of  miR‐223  significantly inhibited cancer cell migration and invasion in  PC a cells.  In silico  database and genome‐wide gene expression analyses revealed that   ITGA 3  and   ITGB 1  were direct targets of  miR‐223  regulation. Knockdown of   ITGA 3  and   ITGB 1  significantly inhibited cancer cell migration and invasion in  PC a cells by regulating downstream signaling. Moreover, overexpression of  ITGA 3 and  ITGB 1 was observed in  PC a clinical specimens. Thus, our data indicated that downregulation of  miR‐223  enhanced   ITGA 3/ ITGB 1  signaling and contributed to cancer cell migration and invasion in  PC a cells. Elucidation of the molecular pathways modulated by tumor‐suppressive mi RNA s provides insights into the mechanisms of  PC a progression and metastasis.

Tumor‐suppressive micro RNA ‐223 inhibits cancer cell migration and invasion by targeting ITGA 3/ ITGB 1 signaling in prostate cancer